Deucrictibant (PHVS719, XR tablet)
Prophylactic treatment of Hereditary Angioedema (HAE) attacks
Key Facts
About Pharvaris
Pharvaris is a clinical-stage biotech focused on transforming the treatment landscape for hereditary angioedema (HAE) and other bradykinin-mediated conditions by developing oral alternatives to current injectable therapies. The company's lead asset, deucrictibant, is a potent, oral small-molecule B2 receptor antagonist being evaluated in two pivotal Phase 3 trials (RAPIDe-3 for on-demand and CHAPTER-3 for prophylaxis) and has shown promising efficacy and safety in Phase 2 studies. With a seasoned leadership team and a clear mission to provide patient choice through convenient, effective oral treatments, Pharvaris is positioned to address significant unmet needs in the rare disease market.
View full company profileAbout Pharvaris
Pharvaris is a clinical-stage biotech focused on transforming the treatment landscape for hereditary angioedema (HAE) and other bradykinin-mediated conditions by developing oral alternatives to current injectable therapies. The company's lead asset, deucrictibant, is a potent, oral small-molecule B2 receptor antagonist being evaluated in two pivotal Phase 3 trials (RAPIDe-3 for on-demand and CHAPTER-3 for prophylaxis) and has shown promising efficacy and safety in Phase 2 studies. With a seasoned leadership team and a clear mission to provide patient choice through convenient, effective oral treatments, Pharvaris is positioned to address significant unmet needs in the rare disease market.
View full company profile